A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver and Stage IV Colorectal Cancer AJCC v8, sponsored by City of Hope Medical Center. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing floxuridine in Colorectal Neoplasms — 5 open to participants now, 6 under way, 3 of them phase 3. Floxuridine · Colorectal Neoplasms.
Among the 27 studies testing floxuridine in Colorectal Neoplasms, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2027, is one of 4 in phase 1, and was the 27th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →5 of the 27 studies testing floxuridine in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
ECOG-ACRIN Cancer Research Group · Sites in United States
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Yuhong Li · Sites in China
Ages 18–70
By country, each count listing its studies:
Floxuridine: first FDA approval 1970 (FUDR). What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9
First in 1994; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 49 across the 25 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 27 have an industry lead sponsor. The 10 most frequent:
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
42 studies in Colorectal Neoplasms by City of Hope Medical Center: 17 open now, 22 under way, 2 of them phase 3. Of 18 finished, 3 (17%) have results posted.
Among the 42 studies in Colorectal Neoplasms by City of Hope Medical Center, this one is the 13th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2027, is one of 11 in phase 1, reaches primary completion later than 8 of the 21 other live ones, and was the 42nd registered.
City of Hope Medical Center’s Colorectal Neoplasms studies by the year they started, since 1994.
1 of the studies testing floxuridine in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01815359Memorial Sloan Kettering Cancer CenterICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing floxuridine in Colorectal Neoplasms, from their registry updates:
Among City of Hope Medical Center’s 42 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This phase I/Ib trial tests the effect of leronlimab in combination with hepatic arterial infusion (HAI) floxuridine (FUDR)and standard of care (SOC) systemic therapy in treating patients with colorectal cancer that has spread from where it first started to the liver (metastatic). Leronlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets, such as CCR5 which is expressed on T cells (a type of immune cell), which may cause the body to make an immune response (antigens) and may also improve the effectiveness of treatment. HAI delivers chemotherapy, such as floxuridine, directly to the liver. Catheters are put into an artery in the groin that leads directly to the liver and drugs are given through the catheters. Floxuridine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of tumor cells in your body. HAI can deliver floxuridine at up to 300 times the concentrations that can be given through the vein. Systemic therapy is treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body. Giving leronlimab in combination with HAI floxuridine and SOC systemic therapy may be safe, tolerable, and/or safe in treating colorectal cancer patients with liver metastases.
PRIMARY OBJECTIVE:
I. To evaluate the feasibility of administering four planned cycles of combined standard-of-care systemic therapy, hepatic arterial infusion (HAI) floxuridine (FUDR), and leronlimab as reflected by relative dose intensity in the study population.
SECONDARY OBJECTIVES:
I. To characterize the safety profile of the combined regimen. II. To evaluate the anti-tumor activity of leronlimab administered subcutaneously alongside HAI pump and systemic therapy in patients with colorectal cancer with liver metastases, as assessed by 1 year and 2 year progression-free survival (PFS) and median progression free-survival.
III. To evaluate liver-specific disease control with leronlimab plus HAI pump and systemic therapy.
IV. To evaluate the anti-tumor activity of Leronlimab administered subcutaneously alongside HAI pump and systemic therapy in patients with colorectal cancer with liver metastases, as assessed by changes in circulating tumor deoxyribonucleic acid (DNA) (ctDNA) and ctDNA clearance.
EXPLORATORY OBJECTIVES:
I. To characterize baseline and on-treatment tissue and circulatory biomarkers of immune evasion and metastatic potential, including PD-L1 expression, immune genomic and phenotypic biomarkers, and circulating tumor cells.
II. To assess liver damage and healing associated with leronlimab plus HAI pump and systemic therapy.
III. To evaluate standard-of-care imaging findings and liver parenchyma for evidence of liver damage and disease progression.
OUTLINE:
Patients receive leronlimab subcutaneously (SC) weekly with SOC systemic therapy for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection with HAI pump placement. Starting 4 weeks after surgery, patients receive floxuridine continuously via HAI pump every 14 days of each cycle and resume leronlimab SC weekly in combination with SOC systemic therapy of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and computed tomography (CT) and/or magnetic resonance imaging (MRI) throughout the study. Additionally, patients may optionally undergo biopsy on study.
After completion of study treatment, patients are followed up at 30 days and then for up to 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Agreement to allow the use of from diagnostic tumor and/or surgical biopsies
Confirmed colorectal cancer with liver dominant metastases amenable and a candidate for adjuvant HAI floxuridine (FUDR) pump therapy as determined by the clinical team.
≥ 8 g/dL (within 14 days prior to day 1 of protocol therapy)
Total ≤ 1.5 x (ULN) (unless has Gilbert's syndrome) (within 14 days prior to day 1 of protocol therapy)
Creatinine ≤ 1.5 x institutional ULN (within 14 days prior to day 1 of protocol therapy) OR
Women of (WOCBP): negative urine or serum pregnancy test (within 14 days prior to day 1 of protocol therapy)
Agreement by females and males of childbearing potential to use an effective method of or abstain from heterosexual activity for the course of the study through at least three months after the last dose of protocol therapy
Exclusion Criteria:
Chemotherapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive leronlimab SC weekly with SOC systemic therapy for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection with HAI pump placement. Starting 4 weeks after surgery, patients receive floxuridine continuously via HAI pump every 14 days of each cycle and resume leronlimab SC weekly in combination with SOC systemic therapy of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study. Additionally, patients may optionally undergo biopsy on study.
Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Floxuridine · Procedure: Intrahepatic Infusion Procedure · Biological: Leronlimab · Procedure: Magnetic Resonance Imaging · Procedure: Surgical Procedure · Procedure: Systemic Therapy
Undergo biopsy
Also known as: Biopsy, BIOPSY_TYPE, Bx
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo CT
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Given via HAI pump
Also known as: 2'-Deoxy-5-fluorouridine, 5-Fluoro-2'-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR 138720, WR-138720, WR138720
Given floxuridine via HAI pump
Also known as: HAI, Hepatic Arterial Infusion, Hepatic Artery Infusion, IHI, Intrahepatic Infusion
Given SC
Also known as: PA14, PRO 140, PRO-140, PRO140, WHO 10751
Undergo MRI
Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Undergo surgical resection with HAI pump placement
Also known as: Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
Given SOC systemic therapy
Also known as: Non-targeted, Non-targeted Therapy, Systemic Treatment
Proportion of patients completing all four planned hepatic arterial infusion (HAI) cycles with a relative dose intensity ≥ 80% for HIA floxuridine (FUDR)
Will be calculated using the number of patients who complete all four planned HAI cycles with a relative dose intensity ≥ 80% for HAI FUDR divided by the total number of enrolled patients.
Time frame: Up to 4 cycles (cycle length = 28 days)
Incidence, type, and severity of adverse events (AEs) attributed to HAI
Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose HAI through 30 days after the last dose of HAI
Incidence of serious AEs attributed to HAI
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose HAI through 30 days after the last dose of HAI
Incidence of AEs attributed to HAI leading to treatment interruption or discontinuation
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose HAI through 30 days after the last dose of HAI
Incidence, type, and severity of AEs attributed to leronlimab
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose leronlimab through 30 days after last dose of leronlimab
Incidence of serious AEs attributed to leronlimab
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose leronlimab through 30 days after last dose of leronlimab
Incidence of AEs leading attributed to leronlimab to treatment interruption or discontinuation
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose leronlimab through 30 days after last dose of leronlimab
Incidence, type, and severity of AEs attributed to systemic therapy
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose systemic therapy through 30 days after last dose of systemic therapy
Incidence of serious AEs attributed to systemic therapy
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose systemic therapy through 30 days after last dose of systemic therapy
Incidence of AEs attributed to systemic therapy leading to treatment interruption or discontuation
Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first dose systemic therapy through 30 days after last dose of systemic therapy
Incidence and extent of liver toxicity attributed to HAI/FUDR requiring dose reductions based on standard of care nomogram
Data will be summarized by incidence, indication, dose delays, dose interruptions, additional intraarterial corticosteroid doses administered, duration of additional intraarterial corticosteroid therapy, and association with treatment hold, dose reduction, or permanent discontinuation of HAI/FUDR. Descriptive statistics will be used to summarize the safety profile.
Time frame: From the first HAI infusion through 30 days after the final dose of HAI therapy
Incidence and characteristics of dose reductions and treatment interruption of HAI/FUDR therapy
Dose reductions will be summarized by incidence, number of dose reductions per patient, time to first dose reduction, primary reason for dose reduction, and lowest dose level reached and whether treatment was subsequently discontinued. Descriptive statistics will be used to summarize the safety profile.
Time frame: From first administration of HAI therapy and up through 30 days after the final administration of HAI therapy
Radiographic progression free survival (PFS)
Will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Will be summarized as the proportion of patients who meet definition. Will be graphically represented using Kaplan-Meier methods.
Time frame: From enrollment to first objective occurrence of tumor progression or death due to any cause, whichever occurs first, assessed up to 1 year
Radiographic PFS
Will be assessed using RECIST v 1.1. Will be summarized as the proportion of patients who meet the definition. Will be graphically represented using Kaplan-Meier methods.
Time frame: From enrollment to first objective occurrence of tumor progression or death due to any cause, whichever occurs first, assessed up to 2 years
Median PFS
Will be graphically represented using Kaplan-Meier methods.
Time frame: Up to 24 months
Median liver-PFS
Will be graphically represented using Kaplan-Meier methods.
Time frame: Up to 24 months
Liver-PFS
Will be graphically represented using Kaplan-Meier methods.
Time frame: From enrollment to the first occurrence of radiographic progression within the liver or death due to any cause, assessed up to 1 year
Liver-PFS
Will be graphically represented using Kaplan-Meier methods.
Time frame: From enrollment to the first occurrence of radiographic progression within the liver or death due to any cause, assessed up to 2 years
Change in circulating tumor deoxyribonucleic acid (ctDNA)
Change in ctDNA will be quantified as the difference between the baseline value and each subsequent measurement. Proportion achieving clearance defined as 100% reduction in the ctDNA will also be reported. Will be quantitatively assessed to determine their correlation with clinical outcomes/findings.
Time frame: At baseline (weeks 0, 2, 4, and 6) and post operatively (weeks 2, 4, 6, 8, 10, 12, 14 and 16)
ctDNA clearance
Will be quantitatively assessed to determine their correlation with clinical outcomes/findings
Time frame: Up to 24 months
Start is estimated for May 2027; primary completion for Feb 2028, 8 months later.
Of 166 non-industry phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 8 months is below that.
Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Floxuridine · Leronlimab